Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Prolonged antigen storage endows merocytic dendritic cells with enhanced capacity to prime anti-tumor responses in tumor-bearing mice.

Reboulet RA, Hennies CM, Garcia Z, Nierkens S, Janssen EM.

J Immunol. 2010 Sep 15;185(6):3337-47. doi: 10.4049/jimmunol.1001619. Epub 2010 Aug 18.

2.

Tumor antigen presentation by dendritic cells.

Petersen TR, Dickgreber N, Hermans IF.

Crit Rev Immunol. 2010;30(4):345-86. Review.

PMID:
20666707
3.

Cutting edge: merocytic dendritic cells break T cell tolerance to beta cell antigens in nonobese diabetic mouse diabetes.

Katz JD, Ondr JK, Opoka RJ, Garcia Z, Janssen EM.

J Immunol. 2010 Aug 15;185(4):1999-2003. doi: 10.4049/jimmunol.1001398. Epub 2010 Jul 19.

4.

The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells.

Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre CA, Ventre E, Vu Manh TP, Baranek T, Storset AK, Marvel J, Boudinot P, Hosmalin A, Schwartz-Cornil I, Dalod M.

J Exp Med. 2010 Jun 7;207(6):1283-92. doi: 10.1084/jem.20100223. Epub 2010 May 17.

5.

Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.

Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, Vulink AJ, Hart DN, Radford KJ.

J Exp Med. 2010 Jun 7;207(6):1247-60. doi: 10.1084/jem.20092140. Epub 2010 May 17.

6.

Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells.

Bachem A, Güttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, Salama A, Movassaghi K, Opitz C, Mages HW, Henn V, Kloetzel PM, Gurka S, Kroczek RA.

J Exp Med. 2010 Jun 7;207(6):1273-81. doi: 10.1084/jem.20100348. Epub 2010 May 17.

7.

Building on dendritic cell subsets to improve cancer vaccines.

Palucka K, Ueno H, Zurawski G, Fay J, Banchereau J.

Curr Opin Immunol. 2010 Apr;22(2):258-63. doi: 10.1016/j.coi.2010.02.010. Epub 2010 Mar 11. Review.

8.

Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance.

Swiecki M, Colonna M.

Immunol Rev. 2010 Mar;234(1):142-62. doi: 10.1111/j.0105-2896.2009.00881.x. Review.

9.

Origin and development of dendritic cells.

Liu K, Nussenzweig MC.

Immunol Rev. 2010 Mar;234(1):45-54. doi: 10.1111/j.0105-2896.2009.00879.x. Review.

PMID:
20193011
10.

Instructive cytokine signals in dendritic cell lineage commitment.

Schmid MA, Kingston D, Boddupalli S, Manz MG.

Immunol Rev. 2010 Mar;234(1):32-44. doi: 10.1111/j.0105-2896.2009.00877.x. Review.

PMID:
20193010
11.

The CD8+ dendritic cell subset.

Shortman K, Heath WR.

Immunol Rev. 2010 Mar;234(1):18-31. doi: 10.1111/j.0105-2896.2009.00870.x. Review.

PMID:
20193009
12.

Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity.

Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, Smyth MJ, Zitvogel L.

Cancer Res. 2010 Feb 1;70(3):855-8. doi: 10.1158/0008-5472.CAN-09-3566. Epub 2010 Jan 19. Review.

13.

Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.

Curran MA, Allison JP.

Cancer Res. 2009 Oct 1;69(19):7747-55. doi: 10.1158/0008-5472.CAN-08-3289. Epub 2009 Sep 8.

14.

Characterization of an immediate splenic precursor of CD8+ dendritic cells capable of inducing antiviral T cell responses.

Bedoui S, Prato S, Mintern J, Gebhardt T, Zhan Y, Lew AM, Heath WR, Villadangos JA, Segura E.

J Immunol. 2009 Apr 1;182(7):4200-7. doi: 10.4049/jimmunol.0802286.

15.

Novel subset of CD8{alpha}+ dendritic cells localized in the marginal zone is responsible for tolerance to cell-associated antigens.

Qiu CH, Miyake Y, Kaise H, Kitamura H, Ohara O, Tanaka M.

J Immunol. 2009 Apr 1;182(7):4127-36. doi: 10.4049/jimmunol.0803364.

16.

Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.

Edukulla R, Woller N, Mundt B, Knocke S, Gürlevik E, Saborowski M, Malek N, Manns MP, Wirth T, Kühnel F, Kubicka S.

Cancer Res. 2009 Feb 15;69(4):1448-58. doi: 10.1158/0008-5472.CAN-08-1160. Epub 2009 Feb 3. Erratum in: Cancer Res. 2011 Mar 1;71(5):2021. Ramakrishna, Edukulla [corrected to Edukulla, Ramakrishna].

17.

Cognate CD4 help is essential for the reactivation and expansion of CD8 memory T cells directed against the hematopoietic cell-specific dominant minor histocompatibility antigen, H60.

Ryu SJ, Jung KM, Yoo HS, Kim TW, Kim S, Chang J, Choi EY.

Blood. 2009 Apr 30;113(18):4273-80. doi: 10.1182/blood-2008-09-181263. Epub 2009 Jan 12.

18.

Dendritic cells: a critical player in cancer therapy?

Palucka AK, Ueno H, Fay J, Banchereau J.

J Immunother. 2008 Nov-Dec;31(9):793-805. doi: 10.1097/CJI.0b013e31818403bc. Review.

19.

Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation.

Mouriès J, Moron G, Schlecht G, Escriou N, Dadaglio G, Leclerc C.

Blood. 2008 Nov 1;112(9):3713-22. doi: 10.1182/blood-2008-03-146290. Epub 2008 Aug 12.

20.

Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I.

Di Pucchio T, Chatterjee B, Smed-Sörensen A, Clayton S, Palazzo A, Montes M, Xue Y, Mellman I, Banchereau J, Connolly JE.

Nat Immunol. 2008 May;9(5):551-7. doi: 10.1038/ni.1602. Epub 2008 Mar 30.

Supplemental Content

Support Center